| IPO Company Profile © ipodata.com |
| Message Board | SEC Filings | Peer IPO Companies |
| Oculex Pharmaceuticals, Inc. |
| 639 N. Pastoria Avenue, Sunnyvale, CA 94086 * (408) 481-0424 |
| Business Description | The company is a leading ophthalmic drug delivery company that has created a novel technology platform to enable the treatment of major diseases and conditions that occur inside the eye. |
|
Filing Information Not yet | |||
| To Trade As | OCLX (NASNTL) | Industry | Pharmaceutical (SIC 2834) |
| Type of Stock Offered | Common Shares | Filing Date | 4/6/00 |
| Domestic Shares Filed | 0 | Filing Price | - - |
| Foreign Shares Filed | 0 | Offering Amount | $70,000,000 |
| Company Shares | 0 | Est. Expenses | - - |
| Selling Shrhldrs Shares | 0 | Post-IPO Shares | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Warburg Dillon Read LLC | Lead Manager | (203) 719-3000 |
| Banc of America Securities LLC | Co-manager | (415) 627-2100 |
| Dain Rauscher Wessels | Co-manager | (612) 371-2818 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | - - Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/97 | 12/31/98 | 12/31/99 | ||||
| Revenues | - | - | 254.000 | 146.000 | 242.000 | - | - |
| Income from Oper. | - | - | -3.555 | -6.344 | -7.237 | - | - |
| Net Income | - | - | -3.326 | -5.969 | -7.179 | - | - |
| E.P.S | - | - | -0.860 | -1.530 | -1.820 | - | - |
| Revenue Growth (%) | - | - | -42.52 | 65.753 | - | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -6.21 | - | - | ||||
| Cash Flow - Inv. | 5.67 | - | - | ||||
| Cash Flow - Fin. | -0.14 | - | - | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 12/31/99 | Financial Ratios | ||||
| Total Assets | 4.54 | Current Assets | 2.95 | Current Ratio | 0.83 |
| Total Liab. | 4.06 | Current Liab. | 3.54 | Debt Ratio | 89.51% |
| Total Equity | 0.48 | Working Cap. | -0.59 | Debt to Equity Ratio | 8.54 |
| Cash | 2.72 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used to fund operations, including continued development and commercialization of existing products and research and development of additional products, to hire additional personnel and expand facilities to meet the needs of growing business and for working capital and for general corporate purposes. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Cooley Godward Castro Huddleson & Tatum |
| Bank's Law Firm | Dewey Ballantine |
| Auditor | Ernst & Young |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Transpac Capital Pte Ltd. | 19.70 | |
| Note: represents ownership of 5% or more prior to the offering. | ||